The effects of L-carnitine supplementation on septic patients
- Conditions
- Sepsis.Other sepsis
- Registration Number
- IRCT20201129049534N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Diagnosis of sepsis based on blood culture and approval of an ICU specialist and anesthesiologist and infectious disease specialist
Gastrointestinal with normal function and intestinal nutrition criteria
Accept informed consent
Age>=18
Patient or family dissatisfaction
Patients who are hospitalized in the ICU for less than 48 hours or do not have the possibility of intestinal feeding and patients who receive nutritional support with full intravenous feeding
Patients who do not have an indication for intestinal nutrition on the first day and are confirmed and predicted based on the diagnosis of the intensive care unit that they will not be able to receive intestinal nutrition in the future. (Nausea, persistent vomiting, ileus, intestinal obstruction, uncontrolled diarrhea (> 500 ml per day), high-output fistula (> 500 ml per day), intestinal inaccessibility, incomplete resuscitation and hemodynamic instability
Cancer patients undergoing chemotherapy and taking cisplatin
Patients taking anticonvulsants (phenobarbital and phenytoin)
Patients taking pivalic acid, valproic acid and Ifosfamide
Patients taking levetiracetam
Patients undergoing dialysis
Patients with hyperthyroidism and hypothyroidism
Pregnancy
Severe and progressive septic shock
Patients who are expected to die within 2 days of admission to the ICU
Patients with BMI<18.5 kg/m2 admitted to the IC
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method C reactive Protein (CRP). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Erythrocyte sedimentation rate (ESR). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Total antioxidant capacity (TAC). Timepoint: At baseline and end f the study. Method of measurement: Commercial diagnostic kit.;Superoxide dismutase (SOD). Timepoint: At baseline and end f the study. Method of measurement: Commercial diagnostic kit.
- Secondary Outcome Measures
Name Time Method 28 mortality rate. Timepoint: End of the study. Method of measurement: Mathematically dividing the number of dead people by the total number of people using hospital records or telephone follow-up.;Complete blood count (CBC). Timepoint: End of the study. Method of measurement: ELISA kits.